MAPT and Alzheimer disease: These guidelines propose that, for research purposes, AD should be defined as a biological construct determined by the presence of pathology as assessed with the *A/T/N* classification system, depending on levels of amyloid-β (Aβ, A), phosphorylated TAU (p-Tau, T) and neurodegeneration (N) [22].